Tag: Alemtuzumab

In a recent meta-analysis of multiple sclerosis (MS) patients treated with alemtuzumab, secondary immune thrombocytopenia (ITP) was noted to occur with a specific incidence rate. This highlights the nuanced answer to the question: *Do people with MS have low platelets?* The association is not direct but is often linked to medication side effects or the broader autoimmune nature of the disease.

While there is no cure for multiple sclerosis (MS), a chronic autoimmune disease affecting millions worldwide, a few powerful disease-modifying therapies (DMTs) originated as or are still classified as chemotherapy agents. This guide explains **which MS drugs are chemotherapy**, explores their mechanisms, and distinguishes them from newer, more targeted immune therapies.